Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday

Key Points

• Q1 2026 earnings due after the market closes on May 11, with analysts forecasting ($0.32) EPS; the company missed the prior quarter (reported ($0.35) vs. consensus ($0.34)) and analysts project about -$1 EPS for the current and next fiscal years.
• Shares traded around $2.43 (market cap ~$443M) and carry a consensus rating of Moderate Buy with a consensus target of $7.67; analyst price targets range from $6 to $14, implying substantial upside expectations.
• Financials show strong short-term liquidity (quick and current ratios of 5.87) and moderate leverage (debt/equity 0.52); insiders hold ~26.9% of shares though some insider selling occurred recently.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) is projected to issue its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:30 PM ET.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). On average, analysts expect Neumora Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neumora Therapeutics Price Performance

Shares of Neumora Therapeutics stock traded down $0.02 during trading on Monday, reaching $2.43. The company's stock had a trading volume of 93,050 shares, compared to its average volume of 1,608,003. The company has a quick ratio of 5.87, a current ratio of 5.87 and a debt-to-equity ratio of 0.52. Neumora Therapeutics has a 12-month low of $0.61 and a 12-month high of $3.65. The company has a market capitalization of $443.02 million, a P/E ratio of -1.67 and a beta of 3.02. The business has a 50 day moving average price of $2.58 and a 200-day moving average price of $2.38.

Analysts Set New Price Targets

A number of analysts recently weighed in on NMRA shares. Mizuho set a $6.00 price target on Neumora Therapeutics in a research note on Monday, January 5th. Guggenheim restated a "buy" rating and issued a $14.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 31st. Needham & Company LLC restated a "buy" rating and issued a $8.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 31st. William Blair upgraded Neumora Therapeutics from a "market perform" rating to an "outperform" rating in a research report on Tuesday, February 17th. Finally, Leerink Partners assumed coverage on Neumora Therapeutics in a research report on Monday, January 12th. They set an "outperform" rating and a $8.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, Neumora Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.67.

Insider Buying and Selling at Neumora Therapeutics

In other news, insider Paul L. Berns sold 9,819 shares of the business's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $3.51, for a total value of $34,464.69. Following the completion of the transaction, the insider directly owned 7,395,185 shares of the company's stock, valued at $25,957,099.35. The trade was a 0.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 23,387 shares of company stock valued at $82,647 over the last ninety days. Insiders own 26.94% of the company's stock.

Hedge Funds Weigh In On Neumora Therapeutics

Institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC acquired a new position in shares of Neumora Therapeutics in the fourth quarter worth $27,000. Virtu Financial LLC acquired a new position in shares of Neumora Therapeutics in the third quarter worth $31,000. Fred Alger Management LLC acquired a new position in Neumora Therapeutics in the fourth quarter valued at $40,000. Canada Pension Plan Investment Board acquired a new position in Neumora Therapeutics in the second quarter valued at $41,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Neumora Therapeutics in the third quarter valued at $44,000. 47.65% of the stock is owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora's product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.